Pancreatic Cancer - KOL Insight

Description

While Merck & Co's Keytruda is seen as a 'game changer' for US patients with unresectable or metastatic microsatellite instability-high (MSI-high) or mismatch repair deficient (dMMR) solid tumours, or tumours that have high mutational burden (TMB-high), do KOLs see its potential in larger PC populations? Will Phase III POLO study readouts impact the use of Lynparza? How do KOLs assess the potential of FibroGen's pipeline CTGF inhibitor pamrevlumab? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the Report Highlights slidedeck and the KOL Bulletins via the Attachments area

Executive summary

Current and future treatment algorithm for PC

Research objectives

Approved drugs

Immunotherapy
- Keytruda (pembrolizumab; Merck & Co.)
- Lynparza (olaparib; AstraZeneca)

Late-stage pipeline drugs

Polyamine inhibitors
- Ivospemin (SBP101; Panbela Therapeutics)
Connective tissue growth factor (CTGF) inhibitors
- Pamrevlumab (FibroGen)
Other novel agents
- Masitinib (AB Science)
- GRASPA (eryaspase; Erytech Pharma)

Early-stage pipeline drugs - anti-PD-1/PD-L1 combinations

Jemperli (dostarlimab; GSK) and Zejula (niraparib; GSK)
- Key insights summary
- Opdivo (nivolumab; Bristol Myers Squibb) and combinations
- PD-L1 t-haNK (ImmunityBio) and Anktiva (ImmunityBio)
- Retifanlimab (Incyte) and elraglusib (9-ING-41; Actuate Therapeutics)

Early-stage pipeline drugs - other novel therapies

Tedopi (OSE 2101; OSE Immunotherapeutics)
- Key insights summary
- NIS793 and spartalizumab (Novartis)
- Nadunolimab (CAN-04; Cantargia)
- Mitazalimab (Alligator Bioscience) and CDX 1140 (Celldex Therapeutics)
- AZD 0171 (AstraZeneca)
- ABTL 0812 (Ability Pharmaceuticals)
- Onvansertib (Cardiff Oncology)
- Temuterkib (Eli Lilly)

Future trends and opportunities in PC treatment

The holy grail of clinically meaningful efficacy of immune checkpoint inhibitors in PC may not be achievable within the next three to five years, but investigators continue to try all angles
- Chemotherapy will remain the cornerstone of treatment in PC for the foreseeable future, but with increasing integration of immunotherapy and novel agents